Corbin Therapeutics Inc.

Corbin Therapeutics (www.corbinthera.com) is a biotech company spun out from our USP15 program led by Dr. Philippe Gros at McGill University. Corbin uses a proprietary drug discovery platform, to screen and identify novel inhibitors of ubiquitin-specific protease 15 (USP15). USP15 has been shown to regulate type 1 interferon and be key in the neuroinflammation pathogenesis. Corbin is at the hit-to-lead stage using proprietary and well-defined in vitro and in vivo models for drug optimization.